18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A
Advinus Therapeutics
Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A
Advinus Therapeutics
Rational design, synthesis, and structure-activity relationships of 5-amino-1H-pyrazole-4-carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors.
Advinus Therapeutics
Discovery of pyrazole carboxylic acids as potent inhibitors of rat long chain L-2-hydroxy acid oxidase.
Advinus Therapeutics
Discovery of a potent and selective small molecule hGPR91 antagonist.
Advinus Therapeutics
Discovery of novel and potent heterocyclic carboxylic acid derivatives as protein tyrosine phosphatase 1B inhibitors.
Advinus Therapeutics
Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
Advinus Therapeutics
Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model.
Advinus Therapeutics
Discovery and pharmacological evaluation of indole derivatives as potent and selective RORĪ³t inverse agonist for multiple autoimmune conditions.
Advinus Therapeutics
Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2's-hydroxy-3's-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors.
Advinus Therapeutics
Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.
Advinus Therapeutics
Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist.
Advinus Therapeutics
Design and synthesis of novel xanthine derivatives as potent and selective A
Advinus Therapeutics
Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.
Merck Sharp and Dohme Research Laboratories